Compare TFX & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFX | IRTC |
|---|---|---|
| Founded | 1943 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.7B |
| IPO Year | 1994 | 2016 |
| Metric | TFX | IRTC |
|---|---|---|
| Price | $124.90 | $126.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $138.75 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 849.2K | 329.0K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,992,713,000.00 | $747,138,000.00 |
| Revenue This Year | $15.97 | $19.60 |
| Revenue Next Year | $5.15 | $15.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $100.18 | $112.31 |
| 52 Week High | $139.67 | $210.01 |
| Indicator | TFX | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 56.20 |
| Support Level | $123.80 | $112.65 |
| Resistance Level | $126.13 | $165.84 |
| Average True Range (ATR) | 4.92 | 5.26 |
| MACD | -0.40 | 0.86 |
| Stochastic Oscillator | 26.60 | 89.29 |
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.